No industry better illustrates the idea of the innovation frontier than biotechnology.
Every biotechnology in use today progressed through an evolutionary path that led to improved performance (better efficacy and safety in treating patients), and, in the process, spawned an industry with global sales of over $300 billion and growing. This has created significant investment opportunities. Today, we see this evolutionary process continuing and even broadening to address a wider diversity of diseases.
In this thought piece, The Rise of Advanced Biotechnology in the Age of Genomics, we explore topics such as:
- A thumbnail sketch of the history of biotechnology
- The biotech innovation frontier
- Information on important progress and investment opportunities in three key areas:
- Antibody engineering
- RNA targeting
- Gene and cell therapy
Intrigued? Complete the form on this page to download this research paper.
This site and the content within is intended for US-based investors only.
The information and views expressed herein are provided for informational purposes only and do not constitute investment advice. Past performance does not guarantee future results. Any projections, outlooks, or estimates contained herein are forward looking statements based on specific assumptions that are current as of the date indicated, subject to change without notice, and should not be construed as indicative of any actual events that have occurred or may occur. The inclusion of particular investments is not intended to represent, and should not be interpreted to imply, a past or current specific recommendation to purchase or sell a security and should be considered in the context of an overall portfolio. Investing in equity securities involves risk and principal loss is possible. Nothing contained herein constitutes investment, legal, tax, or other advice and should not be relied upon in making an investment or other decision. Investors should always obtain and read up-to-date investment services material before deciding whether to appoint an investment advisor.